HEK293/Human Anti-CD19 Stable Cell Line
描述（Description）
HEK293/Human Anti-CD19 Stable Cell Line
應用說明（Application）
Binding assay by FACS and cell based ELISA
生長特性（Growth Properties）
Adherent
篩選標記（Selection Marker）
Puromycin (5 μg/mL)
培養(yǎng)基（Culture Medium）
DMEM medium + 10% FBS
凍存液（Freeze Medium）
10% DMSO + 90% FBS
裝量（Quantity）
1 vial contains at least 5x10^6 cells in 1 ml of 10% DMSO in FBS.
存儲（Storage）
Frozen in liquid nitrogen.
支原體檢測（Mycoplasma Testing）
Negative
無菌檢測（Sterility Testing）
Negative
使用說明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
背景（Background）
Chimeric antigen receptors (CARs) comprise interact domains, of which target cancer cell expressed antigens and allow T cell to efficiently kill the cancer cell. FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. Our CAR-like cells apply the HEK293 cells for the expression of FMC63 which will be presented on the cell membrane. It mimics the real CAR-T cell reaction and it is used as positive control for Anti-CD19 scFv Antibody flow cytometry detection.
Permits & Restrictions
This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
關鍵字： CD19穩(wěn)定細胞系;CD19細胞系;CD19細胞株;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領域提供關鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。